Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3675107010 | Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3675109013 | Product containing precisely bendroflumethiazide 5 milligram and propranolol hydrochloride 160 milligram/1 each prolonged-release oral capsule (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has manufactured dose form | Prolonged-release oral capsule | true | Inferred relationship | Some | ||
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Is a | Propranolol-containing product in oral dose form | false | Inferred relationship | Some | ||
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Is a | Product containing bendroflumethiazide and propranolol (medicinal product) | false | Inferred relationship | Some | ||
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has precise active ingredient | Bendroflumethiazide (substance) | false | Inferred relationship | Some | 2 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has presentation strength denominator unit (attribute) | Capsule (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has precise active ingredient | Propranolol hydrochloride | false | Inferred relationship | Some | 1 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has presentation strength numerator value | 160 | false | Inferred relationship | Some | 1 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 1 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has basis of strength substance (attribute) | Bendroflumethiazide (substance) | false | Inferred relationship | Some | 2 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has presentation strength denominator unit (attribute) | Capsule (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 2 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has presentation strength numerator value | 5 | false | Inferred relationship | Some | 2 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has basis of strength substance (attribute) | Propranolol hydrochloride | false | Inferred relationship | Some | 1 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has unit of presentation | Capsule (unit of presentation) | true | Inferred relationship | Some | ||
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Is a | Bendroflumethiazide-containing product in oral dose form | false | Inferred relationship | Some | ||
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Count of base of active ingredient | 2 | false | Inferred relationship | Some | ||
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Is a | Bendroflumethiazide and propranolol only product in oral dose form | true | Inferred relationship | Some | ||
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Plays role | Diuretic therapeutic role | false | Inferred relationship | Some | ||
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has basis of strength substance (attribute) | Bendroflumethiazide (substance) | true | Inferred relationship | Some | 1 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has basis of strength substance (attribute) | Propranolol hydrochloride | true | Inferred relationship | Some | 2 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has precise active ingredient | Propranolol hydrochloride | true | Inferred relationship | Some | 2 | |
| Bendroflumethiazide 5 mg and propranolol hydrochloride 160 mg prolonged-release oral capsule | Has precise active ingredient | Bendroflumethiazide (substance) | true | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR